Alnylam Pharmaceuticals, Inc. (ALNY)
ALNY Stock Price Chart
Explore Alnylam Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze ALNY price movements and trends.
ALNY Company Profile
Discover essential business fundamentals and corporate details for Alnylam Pharmaceuticals, Inc. (ALNY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Jun 2004
Employees
2.23k
Website
https://www.alnylam.comCEO
Yvonne L. Greenstreet
Description
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
ALNY Financial Timeline
Browse a chronological timeline of Alnylam Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is $2.04, while revenue estimate is $1.32bn.
Earnings released on 30 Apr 2026
EPS came in at $1.51 surpassing the estimated $0.87 by +73.17%, while revenue for the quarter reached $1.17bn , beating expectations by +4.63%.
Earnings released on 12 Feb 2026
EPS came in at $0.82 falling short of the estimated $1.16 by -29.31%, while revenue for the quarter reached $1.10bn , missing expectations by -4.53%.
Earnings released on 30 Oct 2025
EPS came in at $2.90 surpassing the estimated $0.56 by +416.93%, while revenue for the quarter reached $1.25bn , beating expectations by +30.19%.
Earnings released on 31 Jul 2025
EPS came in at $0.32 surpassing the estimated -$0.54 by +158.85%, while revenue for the quarter reached $773.69m , beating expectations by +16.72%.
Earnings released on 1 May 2025
EPS came in at -$0.01 surpassing the estimated -$0.89 by +98.88%, while revenue for the quarter reached $594.19m , beating expectations by +1.55%.
Earnings released on 13 Feb 2025
EPS came in at $0.06 surpassing the estimated -$0.62 by +109.68%, while revenue for the quarter reached $593.17m , beating expectations by +1.81%.
Earnings released on 31 Oct 2024
EPS came in at -$0.50 surpassing the estimated -$0.92 by +45.45%, while revenue for the quarter reached $500.92m , missing expectations by -6.00%.
Earnings released on 1 Aug 2024
EPS came in at $0.56 surpassing the estimated -$1.07 by +152.34%, while revenue for the quarter reached $659.83m , beating expectations by +47.54%.
Earnings released on 2 May 2024
EPS came in at -$0.16 surpassing the estimated -$1.12 by +85.71%, while revenue for the quarter reached $494.33m , beating expectations by +15.50%.
Earnings released on 15 Feb 2024
EPS came in at -$1.10 surpassing the estimated -$1.20 by +8.33%, while revenue for the quarter reached $439.72m , missing expectations by -0.72%.
Earnings released on 2 Nov 2023
EPS came in at $1.15 surpassing the estimated -$1.34 by +185.82%, while revenue for the quarter reached $750.53m , beating expectations by +87.15%.
Earnings released on 3 Aug 2023
EPS came in at -$2.21 falling short of the estimated -$1.72 by -28.49%, while revenue for the quarter reached $318.75m , missing expectations by -9.06%.
Earnings released on 4 May 2023
EPS came in at -$1.40 surpassing the estimated -$1.97 by +28.93%, while revenue for the quarter reached $319.29m , beating expectations by +2.25%.
Earnings released on 23 Feb 2023
EPS came in at -$1.68 surpassing the estimated -$2.13 by +21.13%, while revenue for the quarter reached $335.04m , beating expectations by +6.99%.
Earnings released on 27 Oct 2022
EPS came in at -$3.32 falling short of the estimated -$1.86 by -78.49%, while revenue for the quarter reached $264.31m , missing expectations by -9.38%.
Earnings released on 28 Jul 2022
EPS came in at -$2.29 falling short of the estimated -$1.62 by -41.36%, while revenue for the quarter reached $224.82m , missing expectations by -12.03%.
Earnings released on 28 Apr 2022
EPS came in at -$2.00 falling short of the estimated -$1.93 by -3.63%, while revenue for the quarter reached $213.26m , missing expectations by -11.49%.
Earnings released on 10 Feb 2022
EPS came in at -$2.16 falling short of the estimated -$1.47 by -46.94%, while revenue for the quarter reached $258.54m , beating expectations by +10.67%.
Earnings released on 28 Oct 2021
EPS came in at -$1.72 falling short of the estimated -$1.51 by -13.91%, while revenue for the quarter reached $187.63m , missing expectations by -14.59%.
Earnings released on 3 Aug 2021
EPS came in at -$1.61 falling short of the estimated -$1.57 by -2.55%, while revenue for the quarter reached $220.55m , meeting expectations.
ALNY Stock Performance
Access detailed ALNY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
